Economic analysis of palivizumab in infants with congenital heart disease

Pediatrics

Volumn 114, Issue 6, 2004, Pages 1606-1611

  Yount, Laura E ^a   Mahle, William T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchiolitis; Congenital heart disease defects; Cost analysis

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ACCOUNTING; ARTICLE; BRONCHIOLITIS; CALCULATION; CHILD; CLINICAL PROTOCOL; COHORT ANALYSIS; CONGENITAL HEART DISEASE; CONTROLLED STUDY; COST CONTROL; COST UTILITY ANALYSIS; DRUG COST; HEMODYNAMICS; HOSPITAL COST; HOSPITALIZATION; HUMAN; HYPOTHESIS; MORTALITY; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEASON; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL; CONGENITAL HEART MALFORMATION; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HEALTH CARE COST; INFANT; STATISTICAL MODEL; STATISTICS; VIROLOGY; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BRONCHIOLITIS; COST SAVINGS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HEART DEFECTS, CONGENITAL; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INFANT; MODELS, ECONOMIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 16644380035     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-0224     Document Type: Article

References (36)

1. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virusassociated deaths among US children 1979-1997. J Infect Dis. 2001;183:16-22
2. Moler FW, Khan AS, Meliones JN, Custer JR, Palmisano J, Shope TC. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med. 1992;20:1406-1413
3. Fox JL. IMpact-RSV Study Group report. Pediatrics. 1999;104:994-995
4. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-540
5. Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1447-1452
6. Numa A. Outcome of respiratory syncytial virus infection and a costbenefit analysis of prophylaxis. J Paediatr Child Health. 2000;36:422-427
7. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104:419-427
8. Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003;162:237-244
9. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003;22:823-827
10. Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics. 2001;107(3). Available at: www.pediatrics.org/cgi/content/full/107/3/e32
11. van den HF, Timmers T, Hess J Morphological, haemodynamic, and clinical variables as predictors for management of isolated ventricular septal defect. Br Heart J. 1995;73:49-52
12. US Census Bureau; 2004. Available at: www.census.gov/main/www/cen2000. html
13. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348:1647-1655
14. MedImmune Annual Report 2002. Gaithersburg, MD: MedImmune; 2004
15. US Bureau of Labor Statistics. Employment and Earnings; 2004. Available at: www.bls.gov/bls/wages.htm
16. Willson DF, Landrigan CP, Horn SD, Smout RJ. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr. 2003;143:S142-S149
17. Equitable Life Assurance Society of the United States, Hospital Daily Service Charges. Catalog No 104283. New York, NY: Equitable Life Assurance Company; 1982
18. Chalom R, Raphaely RC, Costarino AT Jr. Hospital costs of pediatric intensive care. Crit Care Med. 1999;27:2079-2085
19. Howard TS, Hoffman LH, Stang PE, Simoes EA. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J Pediatr. 2000;137:227-232
20. Shwartz M, Young DW, Siegrist R. The ratio of costs to charges: how good a basis for estimating costs? Inquiry. 1995;32:476-481
21. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982;307:397-400
22. Allen HD. Exercise Testing in Moss and Adams' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult. Baltimore, MD: Lippincott Williams & Wilkins; 2000
23. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102
24. Arias E, MacDorman MF, Strobino DM, Guyer B. Annual summary of vital statistics - 2002. Pediatrics. 2003;112:1215-1230
25. Strutton DR, Stang PE. Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: Economic-based decision-making. J Pediatr. 2003;143:S157-S162
26. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J. 2003;22:483-490
27. Schrand LM, Elliott JM, Ross MB, Bell EF, Mutnick AH. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother. 2001;35:1186-1193
28. Shireman TI, Braman KS. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid's high-risk children. Arch Pediatr Adolesc Med. 2002;156:1251-1255
29. Langley JM, Wang EE, Law BJ, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr. 1997;131:113-117
30. Leader S, Yang H, DeVincenzo J, Jacobson P, Marcin JP, Murray DL. Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants. Value Health. 2003;6:100-106
31. Robbins JM, Tilford JM, Jacobs RF, Wheeler JG, Gillaspy SR, Schutze GE. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Arch Pediatr Adolesc Med. 1998;152:358-366
32. Johannesson M, Johansson PO, Jonsson B. Economic evaluation of drug therapy: a review of the contingent valuation method. Pharmacoeconomics. 1992;1:325-337
33. Mahle WT, Spray TL, Wernovsky G, Gaynor JW, Clark BJ III. Survival after reconstructive surgery for hypoplastic left heart syndrome: a 15-year experience from a single institution. Circulation. 2000;102:III136 -III141
34. Weintraub WS, Cole J, Tooley JF. Cost and cost-effectiveness studies in heart failure research. Am Heart J. 2002;143:565-576
35. Khongphatthanayothin A, Wong PC, Samara Y, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med. 1999;27:1974-1981
36. Mulla N, Simpson P, Sullivan NM, Paridon SM. Determinants of aerobic capacity during exercise following complete repair of tetralogy of Fallot with a transannular patch. Pediatr Cardiol. 1997;18:350-356